Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   
 

Abstract | Full HTML Article | PDF ecancer 12 869 / https://doi.org/10.3332/ecancer.2018.869

Special Issue

Pre-, pro- and synbiotics in cancer prevention and treatment—a review of basic and clinical research

There is a growing appreciation of the role of the human microbiota in the pathophysiology of cancer. Pre-, pro- and synbiotics are some of the best evidenced means of manipulating the microbiota for therapeutic benefit and their potential role in the prevention and treatment of cancer has garnered significant interest. In this review, we discuss how these agents may have oncosuppressive effects by maintaining intestinal barrier function, immunomodulation, metabolism and preventing host cell proliferation. We highlight the epidemiological and trials-based evidence supporting a role for pre-, pro- and synbiotics in the prevention of cancer. Ultimately, there is more evidence in support of these agents as adjuncts in the treatment of cancer. We discuss their roles in optimising the efficacy and/or minimising the adverse effects of chemotherapy and radiotherapy, antibiotics and surgery. Although we see significant promise in the application of pre-, pro- and synbiotics for clinical benefit in oncology patients, the field is very much in its infancy and oncologists face substantial challenges in advising their patients appropriately.

Keywords: microbiome, cancer, oncology, probiotics, prebiotics, synbiotics

Loading Article Metrics ... Please wait

Related articles

Research: Breast lesions with atypia in percutaneous biopsies, managed with surgery in the last 10 years

Abstract | Full Article | PDF | Spanish Published: 11 Apr 2019 / https://doi.org/10.3332/ecancer.2019.923

Case Report: Primary cardiac angiosarcoma diagnosed in the first trimester of pregnancy

Abstract | Full Article | PDF Published: 09 Apr 2019 / https://doi.org/10.3332/ecancer.2019.922

Clinical Study: Assessing the tolerability and efficacy of first-line chemotherapy in elderly patients with metastatic HER2−ve breast cancer

Abstract | Full Article | PDF Published: 03 Apr 2019 / https://doi.org/10.3332/ecancer.2019.921

Policy: Precision oncology in Latin America: current situation, challenges and perspectives

Abstract | Full Article | PDF | Spanish Published: 03 Apr 2019 / https://doi.org/10.3332/ecancer.2019.920

Research: Experience with concurrent chemoradiotherapy treatment in advanced cervical cancer: results from a hospital in Argentina

Abstract | Full Article | PDF | Spanish Published: 02 Apr 2019 / https://doi.org/10.3332/ecancer.2019.919



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation